Stock Track | CareDx Stock Surges Pre-Market on Impressive Q3 Results

Stock Track11-06

Shares of CareDx (NASDAQ: CDNA), a leading precision medicine company specializing in transplant diagnostics, soared 5.37% in pre-market trading on November 6, 2024. The rally came on the heels of the company's robust third-quarter 2024 financial results, which exceeded analysts' expectations.

CareDx reported a 23% year-over-year increase in revenue to $82.9 million, surpassing analysts' estimates by 2.7%. The company's net loss narrowed significantly by 69% compared to the same period last year, and its earnings per share loss of $0.14 was better than the expected loss of $0.43.

Looking ahead, CareDx forecasts revenue growth of 12% per annum on average over the next three years. While this growth projection lags behind the 21% forecast for the broader US biotechnology industry, it nevertheless reflects the company's continued expansion and potential for further profitability improvements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163262013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163262013","market":"us","top_or_hot":-1,"title":"Stock Track | CareDx Stock Surges Pre-Market on Impressive Q3 Results","media":"Stock Track","content":"<p>Shares of CareDx (NASDAQ: CDNA), a leading precision medicine company specializing in transplant diagnostics, soared 5.37% in pre-market trading on November 6, 2024. The rally came on the heels of the company's robust third-quarter 2024 financial results, which exceeded analysts' expectations.</p>\n\n<p>CareDx reported a 23% year-over-year increase in revenue to $82.9 million, surpassing analysts' estimates by 2.7%. The company's net loss narrowed significantly by 69% compared to the same period last year, and its earnings per share loss of $0.14 was better than the expected loss of $0.43.</p>\n\n<p>Looking ahead, CareDx forecasts revenue growth of 12% per annum on average over the next three years. While this growth projection lags behind the 21% forecast for the broader US biotechnology industry, it nevertheless reflects the company's continued expansion and potential for further profitability improvements.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CareDx Stock Surges Pre-Market on Impressive Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CareDx Stock Surges Pre-Market on Impressive Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-06 22:26 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of CareDx (NASDAQ: CDNA), a leading precision medicine company specializing in transplant diagnostics, soared 5.37% in pre-market trading on November 6, 2024. The rally came on the heels of the...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDNA","symbol_name":"CareDx","start_time":0,"source_url":"","article_id":"1163262013","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163262013","pubTimestamp":1730903194,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of CareDx , a leading precision medicine company specializing in transplant diagnostics, soared 5.37% in pre-market trading on November 6, 2024. The rally came on the heels of the company's robust third-quarter 2024 financial results, which exceeded analysts' expectations.CareDx reported a 23% year-over-year increase in revenue to $82.9 million, surpassing analysts' estimates by 2.7%. The company's net loss narrowed significantly by 69% compared to the same period last year, and its earni","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDNA":"CareDx"},"translate_title":"股票追踪CareDx股价因第三季度业绩令人印象深刻而盘前飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":1},"content_text":"Shares of CareDx (NASDAQ: CDNA), a leading precision medicine company specializing in transplant diagnostics, soared 5.37% in pre-market trading on November 6, 2024. The rally came on the heels of the company's robust third-quarter 2024 financial results, which exceeded analysts' expectations.\nCareDx reported a 23% year-over-year increase in revenue to $82.9 million, surpassing analysts' estimates by 2.7%. The company's net loss narrowed significantly by 69% compared to the same period last year, and its earnings per share loss of $0.14 was better than the expected loss of $0.43.\nLooking ahead, CareDx forecasts revenue growth of 12% per annum on average over the next three years. While this growth projection lags behind the 21% forecast for the broader US biotechnology industry, it nevertheless reflects the company's continued expansion and potential for further profitability improvements.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163262013"}